FY2025 EPS Forecast for Orchestra BioMed Boosted by Analyst

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Chardan Capital raised their FY2025 earnings per share estimates for Orchestra BioMed in a research report issued on Wednesday, April 2nd. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($1.88) per share for the year, up from their previous estimate of ($1.99). Chardan Capital has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.43). Orchestra BioMed had a negative return on equity of 107.04% and a negative net margin of 2,179.33%. The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.79 million.

A number of other research firms have also recently weighed in on OBIO. B. Riley upgraded shares of Orchestra BioMed to a “strong-buy” rating in a research note on Thursday, April 3rd. Barclays started coverage on Orchestra BioMed in a research report on Thursday, January 2nd. They issued an “overweight” rating and a $16.00 price objective on the stock. BTIG Research began coverage on Orchestra BioMed in a research report on Thursday, March 20th. They set a “buy” rating and a $12.00 target price for the company. Finally, HC Wainwright lowered their price target on Orchestra BioMed from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Orchestra BioMed has a consensus rating of “Buy” and a consensus price target of $15.00.

Orchestra BioMed Price Performance

OBIO opened at $2.83 on Monday. The company has a 50 day simple moving average of $4.65 and a two-hundred day simple moving average of $5.09. The firm has a market cap of $107.58 million, a P/E ratio of -1.76 and a beta of 0.62. Orchestra BioMed has a 1-year low of $2.49 and a 1-year high of $8.87.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its position in shares of Orchestra BioMed by 26.0% in the fourth quarter. SG Americas Securities LLC now owns 12,785 shares of the company’s stock worth $51,000 after buying an additional 2,642 shares in the last quarter. Wells Fargo & Company MN increased its stake in Orchestra BioMed by 43.6% in the 4th quarter. Wells Fargo & Company MN now owns 13,156 shares of the company’s stock worth $53,000 after acquiring an additional 3,992 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Orchestra BioMed during the 4th quarter worth approximately $86,000. Bank of America Corp DE boosted its position in shares of Orchestra BioMed by 42.0% during the 4th quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock valued at $95,000 after acquiring an additional 7,036 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Orchestra BioMed by 281.3% during the 3rd quarter. Barclays PLC now owns 31,785 shares of the company’s stock valued at $163,000 after acquiring an additional 23,448 shares during the last quarter. Institutional investors own 53.55% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.